Many Uninsured People Could Lose Access
to Free COVID-19 Testing, Treatment, and Vaccines as Federal Funding
Runs Out
With an impasse in
Congress over additional COVID-19 emergency funding, uninsured people
could lose access to free testing and treatment services, a new KFF
brief explains.
For people without health insurance, the Health Resources and Services
Administration (HRSA) COVID-19 Uninsured Program has reimbursed
hospitals, doctors and other providers for the COVID-19 care and
services that they provide to uninsured people. However, with federal
funds running out, the program is no longer accepting new claims for
testing and treatment services and will stop accepting claims for
administering vaccines on April 5.
Many uninsured
individuals would likely need to pay out of pocket for testing and some
treatment services or rely on safety-net providers absorbing those
additional costs without any way to get reimbursed. So long as supplies
remain available, vaccines would continue to be paid for by the federal
government and people could not be charged, but vaccine providers would
not get paid for administering vaccines to uninsured people and could
restrict access. This could exacerbate existing racial and ethnic
disparities, as people of color are more likely than their White
counterparts to be uninsured and face other potential barriers to
accessing care.
The brief also outlines how the federal government has used previously
authorized funds to purchase COVID-19 tests, medications, and vaccines,
and the implications for efforts to help ensure equitable access to and
ongoing availability of these resources as that funding runs out.
For people with health coverage, including Medicare and Medicaid,
existing rules and protections will ensure that they will continue to
have access to COVID-19 tests, treatment, and vaccines, though some
limits on cost sharing will end when the ongoing federal COVID-19
Public Health Emergency ends. If the federal government is no longer
able to pre-purchase tests, treatment medications, and vaccines,
supplies may run short if and when the next COVID-19 wave hits and
demand increases.
|
No comments:
Post a Comment